GPX4 and triple-negative breast carcinoma: Similarly, in triple-negative breast cancer (TNBC), high GPX4 expression mediates ferroptosis resistance, and the use of GPX4 inhibitors effectively induces ferroptosis and exerts significant antitumor effects (37).